Trial · NCT00777920
Study of Ambrisentan in Participants With Pulmonary Hypertension
NCT00777920, Phase 3, Completed, Gilead Sciences; results first posted 2020-09-30
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Ambrisentan in Participants With Pulmonary Hypertension. Trials, record NCT00777920. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00777920
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Ambrisentan in Participants With Pulmonary Hypertension
- NCT number
- NCT00777920
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 140 participants, actual
- Lead sponsor
- Gilead Sciences
- Conditions
- Pulmonary Hypertension
- Interventions
- Ambrisentan
- First posted
- 2008-10-22
- Last updated
- 2020-09-30
- Results first posted
- 2020-09-30
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With Adverse Events (AEs) Associated With Long-Term Exposure to Ambrisentan | First dose date of study drug up to the date of last dose plus 30 days (Maximum: approximately 550 weeks) |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With Adverse Events (AEs) Associated With Long-Term Exposure to Ambrisentan | First dose date of study drug up to the date of last dose plus 30 days (Maximum: approximately 550 weeks) | The Safety Analysis Set included participants who were enrolled into the study and received at least one dose of study drug. | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Adverse Events (AEs) Associated With Long-Term Exposure to Ambrisentan | Ambrisentan | 90.7 | percentage of participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ambrisentan | 140 | |
| Overall Study | COMPLETED | Ambrisentan | 90 | |
| Overall Study | NOT COMPLETED | Ambrisentan | 50 |
Source ClinicalTrials.gov
Adverse events177
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Ambrisentan | 12 | 140 | |
| other | Iron deficiency anaemia | Blood and lymphatic system disorders | Ambrisentan | 11 | 140 | |
| other | Atrial fibrillation | Cardiac disorders | Ambrisentan | 9 | 140 | |
| other | Palpitations | Cardiac disorders | Ambrisentan | 19 | 140 | |
| other | Right ventricular failure | Cardiac disorders | Ambrisentan | 7 | 140 | |
| other | Hypothyroidism | Endocrine disorders | Ambrisentan | 8 | 140 | |
| other | Cataract | Eye disorders | Ambrisentan | 7 | 140 | |
| other | Abdominal pain | Gastrointestinal disorders | Ambrisentan | 8 | 140 | |
| other | Constipation | Gastrointestinal disorders | Ambrisentan | 9 | 140 | |
| other | Diarrhoea | Gastrointestinal disorders | Ambrisentan | 16 | 140 |
1 to 10 of 177Source ClinicalTrials.gov
See all 177 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Ambrisentan | 39 | 140 |
| Total, other adverse events | Ambrisentan | 112 | 140 |
| Total, serious adverse events | Ambrisentan | 80 | 140 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00777920
GET https://conductscience.org/api/trials/v1/NCT00777920/events?page=2